Journey Medical Corporation announced that its oral rosacea therapy Emrosi has secured a contract with the third major group purchasing organization (GPO), giving the drug access to roughly 85 % of U.S. commercial lives. The contract became effective on April 1 2026, following the company’s earlier agreements with two other top GPOs.
Prior to this announcement, Journey Medical had achieved 29 % coverage of commercial lives in May 2025, 65 % by July 2025, and approximately 100 million lives with two GPOs by March 25 2026. The new agreement now brings the total to over 150 million commercial lives, a substantial expansion that positions Emrosi for broader payer coverage and accelerated prescription uptake among dermatologists.
The expanded coverage is expected to improve gross‑to‑net realization as formulary adoption matures, reduce reliance on the company’s co‑pay bridging program, and strengthen pricing power. These factors should translate into higher sales volume and improved profitability for the high‑margin Emrosi product, which has been a key driver of recent earnings and is central to Journey Medical’s strategy to achieve sustainable cash flow and mitigate its going‑concern warning.
Management emphasized the significance of the milestone: “We are extremely pleased with the completion of this milestone for Emrosi™.” CEO Claude Maraoui added, “Our focus on delivering cost‑effective access to high‑quality dermatology therapies is expected to expand coverage and improve patient access, positioning Emrosi™ for sustained commercial growth.” He also noted, “Now that our contracts have been secured with the three major GPOs, we look forward to continuing to increase coverage for Emrosi™ for patients nationwide by converting access into coverage.” Maraoui concluded that “As formulary adoption continues to increase, we expect there to be less reliance on our co‑pay bridging program and an improvement in profitability for the brand.”
Emrosi’s clinical profile supports the commercial upside: the drug demonstrated statistically significant superiority over Oracea® and placebo in Phase 3 trials for rosacea, a chronic inflammatory skin condition affecting more than 17 million Americans. Journey Medical’s portfolio includes eight FDA‑approved dermatology drugs, and the company’s cash position stood at approximately $24.1 million at the end of 2025. The company has faced financial challenges, including a going‑concern warning, but recent financial reports indicate improvements in revenue, gross margin, and a move toward positive adjusted EBITDA.
The new GPO contract strengthens Journey Medical’s competitive position in the dermatology market, reduces exposure to payer coverage risk, and supports the company’s goal of achieving sustainable cash flow. By securing coverage with all three major GPOs, Journey Medical is better positioned to convert access into prescriptions, which should help the company meet its financial targets and address the risks highlighted in its recent filings.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.